PT‑141 (Bremelanotide) 5mg Research Peptide (RUO)

Description

Overview
PT‑141, also referenced as Bremelanotide, is a synthetic melanocortin receptor
agonist analog supplied in lyophilised form for laboratory research use only.
Preclinical literature examines its binding profile at melanocortin receptor subtypes
(MC3R/MC4R) and associated cAMP‑linked signalling cascades in defined model systems.

Research Context
– Investigated in in vitro assay configurations assessing melanocortin receptor
binding affinity and downstream second‑messenger pathway markers.
– Examined in controlled models referencing GPCR activation profiles and
signal‑transduction readouts.
– Findings are model‑specific and limited to defined experimental conditions.

Format and Documentation
– Lyophilised peptide; nominal content: 5 mg per vial
– Certificate of Analysis (COA) provided for each lot
– Storage guidance for research environments on label/COA

Compliance
For laboratory research use only (RUO). Not for human or veterinary use, diagnostic
or therapeutic applications.

FAQ
What is PT‑141 in research contexts?
A melanocortin receptor agonist analog examined in controlled in vitro models for
receptor binding and GPCR signalling marker readouts.

Do you provide a COA?
Yes — each lot is supplied with a Certificate of Analysis.

How should it be stored in a lab?
Follow the label/COA storage guidance suitable for research environments.

Form: Lyophilised powder
Intended use: Laboratory research use only
Documentation: Certificate of Analysis where applicable
Dispatch: Fast UK fulfilment
Storage:
– Powder: -20°C 3 years ; 4°C 2 years ; 15°C 3 month
– In solvent: -80°C 6 months ; -2°C 1 month ; 10°C 1 week

Product disclaimer
This product is supplied strictly for laboratory research use only. Not for human or veterinary